

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: G01N 33/53, 33/566	A1	(11) International Publication Number: WO 99/27365 (43) International Publication Date: 3 June 1999 (03.06.99)
(21) International Application Number: PCT/US98/24969 (22) International Filing Date: 20 November 1998 (20.11.98) (30) Priority Data: 08/975,614 21 November 1997 (21.11.97) US 09/163,713 30 September 1998 (30.09.98) US (71) Applicant: TULARIK INC. [US/US]; Two Corporate Drive, South San Francisco, CA 94080 (US). (72) Inventors: LUSTIG, Kevin; Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 (US). BAEUERLE, Patrick; Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 (US). BECKMANN, Holger; Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 (US). CHEN, Jin-Long; Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 (US). SHAN, Bei; Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080 (US). (74) Agent: OSMAN, Richard, Aron; Science & Technology Law Group, 75 Denise Drive, Hillsborough, CA 94010 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NUCLEAR HORMONE RECEPTOR DRUG SCREENS (57) Abstract <p>Methods for identifying modulators of nuclear hormone receptor function comprise the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the receptor. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a recited nuclear hormone transcriptional coactivator motif sequence, the sensor is present at sub-micromolar concentration, the binding reaction occurs in solution, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label. Reagents include labeled sensor peptides and reaction mixtures consisting essentially of nuclear hormone receptor, a peptide and a candidate.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Nuclear Hormone Receptor Drug Screens

INTRODUCTION

5 Field of the Invention

The field of this invention is screens for drugs effecting nuclear hormone receptor function.

Background

10 Nuclear hormone receptors comprise a large, well-defined family of ligand-activated transcription factors which modify the expression of target genes by binding to specific cis-acting sequences (Laudet et al., 1992, EMBO J, Vol, 1003-1013; Lopes da Silva et al., 1995, TINS 18, 542-548; Mangelsdorf et al., 1995, Cell 83, 835-839; Mangelsdorf et al., 1995, Cell 83, 841-850). Family members include both orphan receptors and receptors for a wide
15 variety of clinically significant ligands including steroids, vitamin D, thyroid hormones, retinoic acid, etc. Ligand binding is believed to induce a conformational change in the receptors and promote their association with transcriptional coactivators, which are a diverse group of large nuclear proteins (Glass et al., 1997, Curr Opin Cell Biol 9, 222-232), which may share a signature sequence motif (Heery et al., 1997, Nature 733-736). The resulting
20 complex then binds high affinity sites in chromatin and modulates gene transcription.

 The classic approach to identifying agonists or antagonists of nuclear hormone receptors is the ligand displacement assay, where the displacement of radiolabeled ligand by candidate agents is detected. An alternative approach is a cell-based transcription assay for expression of a reporter of nuclear hormone receptor activation (e.g. Evans et al. (1991) US
25 Patent No.5,071,773). More recently, a gel-based coactivator dependent receptor ligand assay (Krey et al., 1997, Mol Endocrinol 11, 779-791) has been used to identify ligands of peroxisome proliferator-activated receptors (PPARs), which are nuclear hormone receptors activated by a variety of compounds including hypolipidemic drugs. Unfortunately, these various assays suffer from a number of limitations including a required known ligand and
30 time, labor and resource intensive cell-based and gel-based methods, respectively.

SUMMARY OF THE INVENTION

The invention provides methods and compositions for efficient screening of modulators of nuclear hormone receptor function, without the use of cell- or gel-based steps. The methods are amenable to automated, cost-effective high throughput screening of chemical libraries for bioactive compounds.

5 In one embodiment, the invention provides in vitro methods comprising the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding
10 with a corresponding unbiased binding of the sensor to the receptor, wherein a difference between the biased and unbiased bindings indicates that the agent modulates a receptor function. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a nuclear hormone transcriptional coactivator motif sequence. To ensure specificity and optimize binding, the sensor is
15 generally present at sub-micromolar concentration and the binding reaction occurs in solution. In a preferred embodiment, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label.

The invention also provides reagents such as labeled sensor peptides and reaction mixtures consisting essentially of nuclear hormone receptor, a peptide and a candidate agent,
20 wherein the peptide provides direct, in vitro ligand-dependent binding to the receptor, especially in which the binding is enhanced in the presence of the agent.

BRIEF DESCRIPTION OF THE FIGURES

- 25 Figure 1. LXR activation dose response with oxysterol ligands in fluorescent polarization assay with TUK-1391 sensor.
- Figure 2. Dose response showing 24-ketocholesterol ligand (2 μ M) increases LXR receptor affinity for labeled peptide sensor in fluorescent polarization assay.
- 30 Figure 3. Dose response showing 9-cis-retinoic acid ligand (1 μ M) increases RXR receptor affinity for labeled peptide sensor in fluorescent polarization assay.

Figure 4. Fluorescent polarization NRH agonist assay validation for LXR/24-ketocholesterol ligand (2 μ M), PPAR γ /BRL49653 (1 μ M) and RXR/9-cis-retinoic acid ligand (1 μ M) with TUK-1391 sensor.

DETAILED DESCRIPTION OF THE INVENTION

5 The methods generally employ a mixture comprising three components: a nuclear hormone receptor, a peptide sensor and a candidate agent, in amounts effective to measure the targeted interactions. Many natural nuclear hormone receptors are modular proteins with discrete functional domains, including a ligand binding domain; see Laudet et al.; Lopes da Silva et al.; Mangelsdorf et al.; supra. The subject receptors encompass such full-length
10 receptors as well as portions of the receptors sufficient to provide differential sensor binding in the presence and absence of a corresponding receptor ligand, agonist and/or antagonist. Such portions generally comprise at least the ligand binding domain of the receptor. A wide variety of molecular and biochemical methods are available for biochemical synthesis, molecular expression and purification of the subject compositions, see e.g. Molecular
15 Cloning, A Laboratory Manual (Sambrook, *et al.* Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, *et al.*, Greene Publ. Assoc., Wiley-Interscience, NY) or that are otherwise known in the art. Exemplary nuclear hormone receptors and corresponding target therapeutic application are listed in Table 1.

20 Table 1. Exemplary nuclear hormone receptors, form (M = monomeric, D = heterodimeric, H = homodimeric), tissue expression and target therapeutic application.

	<u>Receptor</u>	<u>Form</u>	<u>Tissue Expression</u>	<u>Target Therapeutic Application</u>
	NURR1	M/D	Dopaminergic Neurons	Parkinson's Disease
	RZR β M		Brain (Pituitary), Muscle	Sleep Disorders
25	ROR α	M	Cerebellum, Purkinje Cells	Arthritis, Cerebellar Ataxia
	NOR-1	M	Brain, Muscle, Heart, Adrenal, Thymus	CNS Disorders, Cancer
	Rev-ErbA β	H	Brain, Muscle, Spleen	CNS Disorders
	Tlx	H	Embryonic and Adult Brain	CNS Disorders
	NGFI-B β	M/D	Brain	CNS Disorders
30	HZF-2 α	H	Hippocampus	CNS Disorders
	COUP-TF α	H	Brain	CNS Disorders

	COUP-TF β	H	Brain	CNS Disorders
	COUP-TF γ	H	Brain	CNS Disorders
	Nur77	M/D	Brain, Thymus, Adrenals	CNS Disorders
	LXR α	D	Liver, Kidney, Spleen, Adrenals	Hypercholesterolemia
	COR	M	Liver, Pancreas	Hypercholesterolemia
5	Rev-ErbA α	H	Muscle, Brain (Ubiquitous)	Obesity
	HNF4 α	H	Liver, Kidney, Intestine	Diabetes
	TOR	M	Thymus, T Cells, Lymphoma	Immune Disorders
	MB67 α	D	Liver	Metabolic Disorders
	SHP	D	Liver, Heart, Pancreas	Metabolic Disorders
10	FXR	D	Liver, Kidney	Metabolic Disorders
	SF-1	M	Gonads, Pituitary	Metabolic Disorders
	LXR β	D	Kidney (Ubiquitous)	Metabolic Disorders
	GCNF	M/H	Testes, Ovary	Infertility
	TR2-11 α, β	H	Testes	Infertility, Contraception
15	TR4	H	Testes	Infertility, Contraception
	ERR α, β	M	Placenta	Infertility
	DAX-1	M	Testes, Adrenals, Ovary, Liver	Adrenal Hypoplasia, Hypogonadism

The mixture also includes a peptide sensor which provides direct, in vitro, significant
 20 assay detectable binding to the receptor under assay conditions. Accordingly, the sensor
 obviates the need to include a natural coactivator protein of the receptor in the mixture. The
 sensor comprises a receptor binding sequence, generally $L_1X_1X_2L_2L_3$, wherein L_1 - L_3 are
 independently selected from hydrophobic amino acids, preferably leucine or isoleucine, more
 preferably leucine; and X_1 - X_2 are independently selected from any amino acid, preferably any
 25 natural amino acid. The sensor region comprising this sequence generally forms an
 amphipathic alpha helix. Such sequences may be natural coactivator protein motif sequences,
 derived from coactivator motif sequences or consensus sequences thereof, e.g. by step-wise
 mutational analysis, and/or from screens of purely or partly synthetic sequences, e.g.
 randomizing residues and selecting for receptor binding. The sensors are of length and
 30 sequence sufficient to effect the requisite specific binding, generally 50 or fewer, preferably
 24 or fewer, more preferably 12 or fewer residues in length. Accordingly, panels of

predetermined or randomized candidate sensors are readily screened for receptor binding. For example, in the high-throughput fluorescent polarization assay (below), candidate sensors demonstrating specific binding are conveniently identified by enhanced fluorescent polarization, generally an increase of at least about 5, preferably at least about 10, more preferably at least about 20 millipolarization units under optimized binding assay conditions.

5 In a particular embodiment, the sensors demonstrate ligand, agonist and/or ligand dependent binding i.e. the sensor differentially binds the receptor in the presence and absence of such ligand/agonist/antagonist, generally differential binding of at least 10/10%, preferably at least 100/50%, more preferably at least 1,000/90%, respectively. Accordingly, panels of predetermined or randomized candidate sensors are readily screened for differential binding, as exemplified in Figures 2 and 3 for two exemplary receptor/ligand pairs. Analogously, differential binding is conveniently demonstrated using known agonists or antagonists of targeted receptors. For orphan receptors, it is often convenient to prescreen known ligands for pseudo-ligands or surrogates which selectively bind the ligand binding domain. Alternatively, agonists and/or antagonists may be identified by screening predetermined or randomized candidate labeled peptides for sensors which demonstrate assay detectable receptor binding, and then screening for agents which increase/decrease the binding of the identified sensor to the receptor, i.e. agonists/antagonists, respectively.

Exemplary sensors and binding data are shown in Table 2.

Table 2. Sensors Activity: Fluorescent Polarization Assay

20	<u>Sensor</u>	<u>Label</u>	<u>Sequence</u>	<u>LXR</u>	<u>PPARγ</u>	<u>RXR</u>
	<u>SRC-1 632-640</u>					
	TUK-1384	F-	KL VQL LTTT (SEQ ID NO:1)	I	O	O
	TUK-1386	F-G-	KL VQL LTTT	I	O	O
	TUK-1385	R-	KL VQL LTTT	II+	I	II+
25	TUK-1387	R-G-	KL VQL LTTT	+	O	II
	<u>SRC-1 689-696</u>					
	TUK-1370	F-	IL HRLLQE (SEQ ID NO:2)	II	O	II
	TUK-1371	R-	IL HRLLQE	IV	I+	IV
	TUK-1373	R-G-	IL HRLLQE	II	O	II+
30	<u>SRC-1 748-755</u>					
	TUK-1390	F-	LL RYLLDK (SEQ ID NO:3)	IV	II	II+

	TUK-1392	F-G-	LLRYLLDK	II+	I	I
	TUK-1391	R-	LLRYLLDK	IV	II+	IV
	TUK-1393	R-G-	LLRYLLDK	III+	I	II+
	<u>SRC-1 748-754</u>					
	TUK-1453	R-	LLRYLLD (SEQ ID NO:4)	III	I	I+
5	<u>SRC-1 749-754</u>					
	TUK-1455	R-	LRYLLD (SEQ ID NO:5)	IV	I+	I
	<u>SRC-1 748-753</u>					
	TUK-1457	R-	LLRYLL (SEQ ID NO:6)	II	+	I
	<u>SRC-1 749-753</u>					
10	TUK-1459	R-	LRYLL (SEQ ID NO:7)	III	I	O
	<u>SRC-1 748-756</u>					
	TUK-1472	R-	LLRYLLDKD (SEQ ID NO:8)	IV	II	IV
	<u>SRC-1 747-756</u>					
	TUK-1473	R-	QLLRYLLDKD (SEQ ID NO:9)	IV	I+	I+
15	<u>SRC-1 746-756</u>					
	TUK-1474	R-	HQLLRYLLDKD (SEQ ID NO:10)	IV	O	I
	<u>SRC-1 1427-1440</u>					
	TUK-1395	F-	PQAQKSLQQLLT (SEQ ID NO:11)	O	O	O
	TUK-1397	F-G-	PQAQKSLQQLLT	O	O	O
20	TUK-1398	R-G-	PQAQKSLQQLLT	O	O	O
	<u>SRC-1 1434-1441</u>					
	TUK-1380	F-	LLQQLLTE (SEQ ID NO:12)	II+	O	O
	TUK-1382	F-G-	LLQQLLTE	II+	O	O
	TUK-1381	R-	LLQQLLTE	IV	I+	I+
25	TUK-1383	R-G-	LLQQLLTE	II	O	O
	<u>RIP-140 496-506</u>					
	TUK-1374	F-	VTLLQLLLG (SEQ ID NO:13)	IV	I	O
	TUK-1376	F-G-	VTLLQLLLG	II+	+	O
	TUK-1375(1433)	R-	VTLLQLLLG	IV	I	O
30	TUK-1377	R-G-	VTLLQLLLG	II	I	+

Synthetic sequence peptides

TUK-1560	R-	ILRKLLQE (SEQ ID NO:14)	IV	II	IV
TUK-1559	R-	ILKRLLE (SEQ ID NO:15)	IV	0	IV
TUK-1558	R-	ILRRLLQE (SEQ ID NO:16)	III	0	IV
TUK-1557	R-	ILKKLLQE (SEQ ID NO:17)	III+	0	IV

5 The sensor also comprises a detectable label. A wide variety of labels may be used including labels providing for direct detection such as radioactivity, luminescence, optical or electron density, etc. or indirect detection such as an epitope tag, etc. A variety of methods may be used to detect the label depending on the nature of the label and other assay components, e.g. through optical or electron density, radiative emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, etc. In a particular embodiment, the label is differentially detectable according to receptor binding, obviating the need for any bound versus unbound separation step. In a more particular embodiment, the label is a fluorescent label which provides differential fluorescence polarization depending on receptor binding. Exemplary such labels include rhodamine and fluorescein, which may be coupled directly or indirectly through a linker, e.g. an amino acid linker. Suitable labels and methods for peptide conjugation/incorporation (e.g. during solid phase peptide synthesis) are well known in the art. The sensor is generally present at a concentration of less than about 1 μ M, preferably less than about 100 nM, more preferably less than about 10 nM and most preferably less than about 1 nM.

20 The assay mixture also comprises a candidate agent. Suitable candidate agents encompass numerous chemical classes, though typically they are organic compounds; preferably small organic compounds and are obtained from a wide variety of sources including libraries of synthetic or natural compounds. In a particular embodiment, the assay mixture also comprises a known ligand of the receptor. This embodiment is particularly suitable for screening for antagonists of the receptor. A variety of other reagents may also be included in the mixture. These include reagents like salts, buffers, neutral proteins, e.g. albumin, detergents, protease inhibitors, etc. may be used.

25 The mixture is incubated under conditions whereby, but for the presence of the candidate agent, the sensor binds the receptor with a reference binding affinity. In a particular embodiment, all the components of the mixture, including the receptor, peptide and agent, are in solution. The mixture components can be added in any order that provides for the requisite

bindings and incubations may be performed at any temperature which facilitates optimal binding. Incubation periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening. After incubation, the agent-biased binding between the sensor and receptor is detected according to the nature of the label, as described above. A difference in the binding in the presence and absence of the agent indicates that the agent modulates a receptor binding function. A difference, as used herein, is statistically significant and preferably represents at least a 50%, more preferably at least a 90% difference.

A wide variety of methods may be used to measure binding between the sensor and the receptor, depending on the nature of the sensor and nuclear hormone receptor, whether the assay is performed in solution or partly or fully in solid phase, whether luminescent, radioactive or fluorescent emissions are used, whether the sensor or the receptor of immobilized receptor-sensor complexes is detected, etc. In solid phase embodiments, the measuring step may involve, inter alia, immobilizing the receptor through the sensor or the sensor through the receptor. For example, the sensor is considered to comprise a label, such as a tag or the amino acids of the sensor itself may provide an epitope label. Hence, the receptor may be immobilized through the sensor and the sensor immobilized through the label. The label may be directly coupled to the solid phase by conventional covalent and/or noncovalent linkages, or be coupled indirectly through one or more second receptors, specific for the label, such as sensor epitope specific antibodies, avidin (where the label is biotin), etc. Where the sensor is so immobilized, the measuring step generally comprises detecting the immobilized nuclear hormone receptor, such as with a receptor-specific antibody, as in a conventional ELISA format. Preferred ELISA format assays employ a chemiluminescent or time-resolved fluorescent substrate for convenient readout, especially in high throughput applications.

In alternative solid phase embodiments, the sensor and receptor are reversed, i.e. the sensor is immobilized through the nuclear hormone receptor. Similarly, the receptor may be directly immobilized, or coupled through one or more receptor-specific receptors and the immobilized sensor may then be detected directly or indirectly, e.g. in an ELISA-type format.

The solid phase assays are particularly useful when a plurality of different sequence sensors are sought to be screened simultaneously or in parallel, in panels or mixtures. For example, with orphan receptors, weakly binding peptides are identified in phage display binding assays. Mixtures of weakly binding peptides are used to screen libraries for

compounds which modulate peptide binding, and positive mixtures are then separated and assayed by individual peptides. Such active peptides are then directly labeled, e.g. with a fluorescent moiety, for use, e.g. in extremely high throughput solution phase assays, such as the fluorescent polarization assay described below. Panels of such peptides may also be used to screen candidate modulators of known receptors, providing a series of binding effects which constitute a virtual fingerprint of the activity/specificity of a given modulator. In addition, such peptides may be used to identify preferred controls for solution phase assays which require a directly detectable sensor peptide.

The invention also provides reagents for use in the subject methods. For example, the invention provides sensors consisting of, or consisting essentially of, a peptide comprising the sequence $L_1X_1X_2L_2L_3$ covalently coupled to a detectable label, wherein L_1 - L_3 are independently selected from hydrophobic amino acids and X_1 - X_2 are independently selected from any amino acid and wherein the peptide provides direct, in vitro ligand-dependent binding to a nuclear hormone receptor. In a particular embodiment, the label is a fluorescent label coupled to the N-terminus of the peptide and the peptide is 24, preferably 18, more preferably 12, most preferably 8 or fewer residues in length. The invention also provides reagent mixtures, such as a mixture consisting essentially of nuclear hormone receptor, a peptide and a candidate agent, wherein the peptide provides direct, in vitro ligand-dependent binding to the receptor, preferably wherein the binding is enhanced in the presence of the agent.

The following example is offered by way of illustration and not by way of limitation.

EXAMPLES

I. High-Throughput In Vitro Fluorescence Polarization Assay

Reagents:

Sensor:	Rhodamine-labeled $L_1X_1X_2L_2L_3$ peptide (final conc. = 1 - 5 nM)
Receptor:	Glutathione-S-transferase/nuclear hormone receptor ligand binding domain fusion protein (final conc. = 100 - 200 nM)
Buffer:	10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6

Protocol:

1. Add 90 microliters of peptide/NHR mixture to each well of a 96-well microtiter plate.

2. Add 10 microliters of test compound per well.
3. Shake 5 min and within 5 minutes determine amount of fluorescence polarization by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc).

5 II. Conformational Sensor - ELISA Format Assay

Buffer and Solution Preparation:

1. 10X Assay Buffer:
100mL of 1M Hepes
300mL of 5M NaCl
20mL of 1M MgCl
Add MQ H₂O to 1L
2. Master Mix of Ligand / peptide / protein
Protein: final conc = 100 nM
Biotin - peptide (MW: 1366.7387g/mole): final conc = 1 uM
Add Assay Buffer and H₂O to bring to final volume: final buffer conc = 1X
3. Antibody Mix:
anti-GST, rabbit (final conc. = 1:10,000)
anti-rabbit-HRP (final conc. = 1:10,000)
Add T-TBS to bring to final volume: final buffer conc = 1X

20 Procedure:

1. Make 50 mL of Master Mix (see 2 above) of appropriate peptide / protein combinations (use 50 mL polypropylene tubes). Incubate for 1 hr at RT
2. Add 95 uL of Master Mix to each well of a 96-well plate**
** Reacti-Bind Streptavidin-Coated, White Polystyrene Plates (#15118B), which have been blocked by Super-Blocking Reagent from Pierce.
3. Transfer 5 uL of each test compound (stock = 60 uM) to each well of the plate
4. Incubate plate for 1 hr at RT
5. While incubating, make rabbit anti-GST antibody and anti-rabbit-HRP Antibody Mix (see 3 above). Incubate on ice for 1 hr.
6. Wash plates 3X with H₂O thoroughly
7. Add 100 uL of Antibody Mix into each well of the plate

8. Incubate for 1 hr at RT
9. Wash 3X with H₂O
10. Dilute Supersignal substrate (mixed Luminol and peroxide) in 1:2 H₂O and then add 100 uL into each well
11. Shake 3-5 min. Read chemiluminescence.

5

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

10

SEQUENCE LISTING

<110> Lustig, Kevin
Baeuerle, Patrick
Beckmann, Holger
Chen, Jin-Long
5 Shan, Bei

<120> Nuclear Hormone Receptor Drug Screens
<130> T97-012-1
<140>
10 <141>
<150> 08/975,614
<151> 1997-11-21
<160> 18
<170> PatentIn Ver. 2.0
15

<210> 1
<211> 9
<212> PRT
<213> Artificial Sequence
20 <220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 1
Lys Leu Val Gln Leu Leu Thr Thr Thr
1 5

25 <210> 2
<211> 8
<212> PRT
<213> Artificial Sequence
30 <220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 2
Ile Leu His Arg Leu Leu Gln Glu
1 5

35 <210> 3
<211> 8
<212> PRT
<213> Artificial Sequence
40 <220>
<223> Description of Artificial Sequence: NHR Sensor Peptides

- <400> 3
Leu Leu Arg Tyr Leu Leu Asp Lys
1 5
- 5 <210> 4
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
- 10 <400> 4
Leu Leu Arg Tyr Leu Leu Asp
1 5
- 15 <210> 5
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
- 20 <223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 5
Leu Arg Tyr Leu Leu Asp
1 5
- 25 <210> 6
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
- 30 <223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 6
Leu Leu Arg Tyr Leu Leu
1 5
- 35 <210> 7
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
- 40 <223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 7

Leu Arg Tyr Leu Leu
1 5

<210> 8
<211> 9
5 <212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 8

10 Leu Leu Arg Tyr Leu Leu Asp Lys Asp
1 5

<210> 9
<211> 10
15 <212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 9

20 Gln Leu Leu Arg Tyr Leu Leu Asp Lys Asp
1 5 10

<210> 10
<211> 11
25 <212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 10

30 His Gln Leu Leu Arg Tyr Leu Leu Asp Lys Asp
1 5 10

<210> 11
<211> 14
35 <212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 11

40 Pro Gln Ala Gln Gln Lys Ser Leu Leu Gln Gln Leu Leu Thr
1 5 10

5 <210> 12
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 12
Leu Leu Gln Gln Leu Leu Thr Glu
1 5

10 <210> 13
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 13
Val Thr Leu Leu Gln Leu Leu Gly
1 5

20 <210> 14
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 14
Ile Leu Arg Lys Leu Leu Gln Glu
1 5

30 <210> 15
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
<400> 15
Ile Leu Lys Arg Leu Leu Gln Glu
1 5

40 <210> 16

<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
5 <400> 16
Ile Leu Arg Arg Leu Leu Gln Glu
1 5

<210> 17
10 <211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NHR Sensor Peptides
15 <400> 17
Ile Leu Lys Lys Leu Leu Gln Glu
1 5

<210> 18
20 <211> 5
<212> PRT
<213> Artificial Sequence
<220>
<221> DOMAIN
25 <222> (1) .. (5)
<223> Description of Artificial Sequence: NHR Sensor Peptides;
first, fourth and fifth residue are independently
selected from hydrophobic amino acids; second and
third residues are independently selected from any
30 amino acid.
<400> 18
Xaa Xaa Xaa Xaa Xaa
1 5

35

WHAT IS CLAIMED IS:

1. An in vitro assay for modulators of a nuclear hormone receptor function, comprising steps:
 forming a mixture comprising a first nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the first receptor, wherein the sensor provides direct, assay detectable binding to the first receptor under assay conditions
 5 measuring an agent-biased binding of the sensor to the first receptor;
 comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the first receptor;
 wherein a difference between the biased and unbiased bindings indicates that the
 10 agent modulates a function of the first receptor.
2. A method according to claim 1, wherein the first receptor comprises the ligand binding domain of PPAR γ , Cyp7PBP(LRH-1), NURR1, RZR β , ROR α , NOR-1, Rev-ErbA β , Tlx, NGFI-B β , HZF-2 α , COUP-TF α , β , γ , Nur77, LXR α , COR, Rev-ErbA α , HNF4 α , TOR,
 15 MB67 α , SHP, FXR, SF-1, LXR β , GCNF, TR2-11 α , β , TR4, ERR α , β and DAX-1
3. A method according to claim 1, wherein the agent effects an increase in binding of the sensor to the first receptor.
- 20 4. A method according to claim 1, wherein the sensor is at a concentration of less than about 10 nM.
5. A method according to claim 1, wherein the sensor comprises an amphipathic alpha helix.
 25
6. A method according to claim 1, wherein the sensor comprises the sequence L₁X₁X₂L₂L₃, wherein L₁-L₃ are independently selected from hydrophobic amino acids and X₁-X₂ are independently selected from any amino acid.
- 30 7. A method according to claim 1, wherein the sensor comprises a peptide sequence selected from KLVQLLT_{TT} (SEQ ID NO:1), ILHRL_LLQE (SEQ ID NO:2), LLRYLLDK

(SEQ ID NO:3), LLRYLLD (SEQ ID NO:4), LRYLLD (SEQ ID NO:5), LLRYLL (SEQ ID NO:6), LRYLL (SEQ ID NO:7), LLRYLLDKD (SEQ ID NO:8), QLLRYLLDKD (SEQ ID NO:9), HQLRYLLDKD (SEQ ID NO:10), PQAQKSLQQLLT (SEQ ID NO:11), LLQQLLTE (SEQ ID NO:12), VTLLQLLG (SEQ ID NO:13), ILRKLLQE (SEQ ID NO:14), ILKRLLQE (SEQ ID NO:15), ILRLLQE (SEQ ID NO:16) and ILKKLLQE (SEQ ID NO:17).

5

8. A method according to claim 1, wherein the first receptor, peptide and agent are in solution.

10

9. A method according to claim 1, wherein the peptide comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label.

15

10. A method according to claim 1, wherein the mixture further comprises a ligand of the first receptor.

11. A method according to claim 1, wherein the sensor provides direct, assay detectable, ligand dependent binding to the first receptor under assay conditions.

20

12. A mixture consisting essentially of a nuclear hormone receptor, a candidate agent and a peptide comprising the sequence $L_1X_1X_2L_2L_3$ covalently coupled to a detectable label, wherein L_1 - L_3 are independently selected from hydrophobic amino acids and X_1 - X_2 are independently selected from any amino acid and wherein the peptide provides direct, in vitro ligand-dependent binding to the receptor.

25

13. The mixture of claim 12, in which the binding is enhanced in the presence of the agent.

30

14. A mixture consisting essentially of a nuclear hormone receptor, a ligand of the receptor, a candidate agent, and a peptide comprising the sequence $L_1X_1X_2L_2L_3$ covalently coupled to a detectable label, wherein L_1 - L_3 are independently selected from hydrophobic

amino acids and X_1 - X_2 are independently selected from any amino acid and wherein the peptide provides direct, in vitro ligand-dependent binding to a nuclear hormone receptor.

15. A sensor consisting essentially of a peptide comprising the sequence $L_1X_1X_2L_2L_3$ covalently coupled to a detectable label, wherein L_1 - L_3 are independently selected from hydrophobic amino acids and X_1 - X_2 are independently selected from any amino acid and wherein the peptide provides direct, in vitro ligand-dependent binding to a nuclear hormone receptor.
16. A sensor according to claim 15, wherein the label is a fluorescent label coupled to the N-terminus of the peptide and the peptide is 12 or fewer residues in length.
17. A method according to claim 1, wherein the measuring step comprises detecting the sensor of immobilized first receptor-sensor complexes.
18. A method according to claim 1, wherein the measuring step comprises detecting the receptor of immobilized first receptor-sensor complexes.
19. A method according to claim 1, wherein the measuring step, the first receptor is immobilized through the sensor.
20. A method according to claim 1, wherein the sensor comprises a label and wherein the measuring step, the first receptor is immobilized through the sensor and the sensor is immobilized through the label.
21. A method according to claim 1, wherein the sensor comprises a label and wherein the measuring step, the first receptor is immobilized through the sensor, and the sensor is immobilized through the label by a second receptor.
22. A method according to claim 1, wherein the sensor comprises a label and wherein the measuring step, the first receptor is immobilized through the sensor, and the sensor is immobilized through the label by a second receptor and wherein the measuring step

comprises detecting the immobilized first receptor.

23. A method according to claim 1, wherein the sensor comprises a label and wherein the measuring step, the first receptor is immobilized through the sensor, and the sensor is immobilized through the label by a second receptor and wherein the measuring step
5 comprises detecting the immobilized first receptor with a third receptor.

24. A method according to claim 1, wherein the sensor comprises an epitope label, wherein the measuring step, the first receptor is immobilized through the sensor and the sensor is immobilized through the label by a second receptor comprising an immobilized
10 epitope label-specific antibody moiety.

25. A method according to claim 1, wherein the sensor comprises a biotin label and wherein the measuring step, the first receptor is immobilized through the sensor and the sensor is immobilized through the label by a second receptor comprising an immobilized
15 avidin moiety.

26. A method according to claim 1, wherein the measuring step, the sensor is immobilized through the first receptor.

27. A method according to claim 1, wherein the measuring step, the sensor is immobilized through the first receptor and the first receptor is immobilized through a second
20 receptor.

28. A method according to claim 1, wherein the measuring step, the sensor is immobilized through the first receptor and the first receptor is immobilized through a second
25 receptor and wherein the measuring step comprises detecting the immobilized sensor.

29. A method according to claim 1, wherein the measuring step, the sensor is immobilized through the first receptor and the first receptor is immobilized through a second
30 receptor and wherein the measuring step comprises detecting the immobilized sensor with a third receptor.

21





FIG. 1

**FIG. 2**





FIG. 3

**FIG. 4**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/24969**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : G01N 33/53, 33/566

US CL : 435/7.1, 7.8

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1, 7.8

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MANGELSDORF et al. The RXR heterodimer and orphan receptors. Cell. 15 December 1995, Vol. 83, pages 841-859.	1-30



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 MARCH 1999

Date of mailing of the international search report

31 MAR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL PAK

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/24969

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, STN, BIOSCIENCE, MEDLINE, CAPLUS, BIOSIS, GENBANK, PIR

search terms: nuclear receptor, co-activator, sensor, ligand bind, steroid receptor

THIS PAGE BLANK (USPTO)